We are studying whether adding gemtuzumab ozogamicin to standard chemotherapy helps reduce minimal residual disease in adults with newly diagnosed acute myeloid leukemia. This research aims to improve treatment outcomes and overall survival.
Health conditions and diseases that the clinical trial is designed to study and treat.
Favorable-intermediate-risk Acute Myeloid Leukemia (AML) is a type of cancer that affects the blood and bone marrow, characterized by the presence of immature blood cells. This classification indicates a better prognosis compared to other types of AML.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Don't worry if you don't know the medicines tested in the trial. There is a chance you have heard about the similar medicines. Check the list below to see if you are familiar with any of them.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.